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Dbl-related oncoproteins are guanine nucleotide exchange
factors specific for Rho-family GTPases and typically possess
tandem Dbl homology (DH) and pleckstrin homology do-
mains that act in concert to catalyze exchange. Because the
ability of many Dbl-family proteins to catalyze exchange is
constitutively activated by truncations N-terminal to their
DH domains, it has been proposed that the activity of Dbl-
family proteins is regulated by auto-inhibition. However, the
exact mechanisms of regulation of Dbl-family proteins
remain poorly understood. Here we show that the Dbl-family
protein, Tim, is auto-inhibited by a short, helical motif imme-
diately N-terminal to its DH domain, which directly occludes
the catalytic surface of the DH domain to prevent GTPase
activation. Similar to the distantly related Vav isozymes,
auto-inhibition of Tim is relieved by truncation, mutation, or
phosphorylation of the auto-inhibitory helix. A peptide com-
prising the helical motif inhibits the exchange activity of Tim
in vitro. Furthermore, substitutions within the most highly
conserved surface of the DH domain designed to disrupt
interactions with the auto-inhibitory helix also activate the
exchange process.
RhoA, Rac1, and Cdc42 are the best understood of the 22
human Rho-family GTPases, which comprise one of five
branches of the Ras superfamily of small GTPases (1). Like Ras,
Rho proteins function as binary switches that alternate between
inactive, GDP-bound states and active, GTP-bound states.
Once activated, RhoGTPases directly engage numerous down-
stream effectors to modulate their functions. Active Rho
GTPases and their effectors orchestrate actin cytoskeleton
rearrangement and gene transcription to coordinate diverse
cellular processes including adhesion, migration, phagocytosis,
cytokinesis, neurite extension and retraction, polarization,
growth, and survival (2).Not surprisingly, aberrant activation of
Rho GTPases promotes various developmental, immunologi-
cal, and proliferative disorders (3).
The Dbl-family of guanine nucleotide exchange factors
(GEFs)5 are the largest group of proteins directly responsible
for the activation of Rho GTPases. Dbl-family proteins are
characterized by aDbl-homology (DH) domain, which contacts
the Rho GTPase to catalyze nucleotide exchange, and an asso-
ciated pleckstrin homology (PH) domain, which fine-tunes the
exchange process by a variety of mechanisms related to the
binding of phosphoinositides. The 69 human Dbl-family pro-
teins are divergent in regions outside the DH/PH module, and
contain additional domains that presumably dictate unique cel-
lular functions (4).
The capacity of DH domains to activate Rho GTPases is
tightly regulated through a multitude of diverse mechanisms
ranging from alterations in transcript levels and protein expres-
sion (5) to subcellular re-distribution (6), post-translationmod-
ifications (7), and protein degradation (8). However, despite
this large spectrum of regulatory mechanisms, in most cases,
truncation of Dbl-family proteins often potently activates their
exchange activities (9). Currently, there is no general under-
standing for why truncation promotes unregulated exchange.
To better understand potential mechanisms that regulate
Dbl-family proteins, we have chosen to study the relatively
small, human Dbl-member, Tim (transforming immortalized
mammary). Timwas originally identified based upon its capac-
ity to induce transformation of NIH 3T3 cells upon truncation
(10), andwhereas there aremultiple transcripts of TIM (10, 11),
endogenous Tim is expressed as a 60-kDa protein, consisting of
a short N-terminal region (70 residues) followed by a DH/PH
cassette and an adjacentC-terminal SH3domain. All conserved
homologs of Tim preserve this domain architecture. mRNA
transcripts encoding Tim are expressed in numerous tissues
and cancer-derived cell lines; corresponding protein expression
has been verified in various cell lines (10, 11). The gene encod-
ing human Tim has been localized to chromosomal region
7q33–7q35, which has been implicated in rearrangements con-
tributing to both acute myelogenous leukemia and breast car-
cinoma (12). Nonetheless, whereas Tim was originally identi-
fied as an oncogene, its in vivo functions and regulation are
unknown. Indeed, although Tim was cloned from a cDNA
expression library derived from a human mammary epithelial
cell line, Tim expression is down-regulated in breast carcinoma
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cell lines and aggressive primary breast carcinoma cells express
versions of Tim in which the catalytic DH domain is either
truncated or mutated, suggesting a possible tumor suppressor
function for Tim (13).
Here we show that the exchange potential of Tim toward
RhoA is inhibited by a shortN-terminal regionwith high helical
propensity that directly interacts with the DH domain to pre-
vent access of Rho GTPases to the DH domain. Truncation,
mutation, or phosphorylation of this putative helix fully relieves
this auto-inhibition. Addition of the putative helix in trans to
truncated Tim restores inhibition. Furthermore, a substitution
within theDHdomain designed to disrupt interactionswith the
N-terminal helix also relieves auto-inhibition. These results
show that Tim, like the distantly related Vav isozymes,
is activated by unintentional truncation and regulated
phosphorylation.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—Full-length and trun-
cated versions of human Tim were PCR-amplified and ligated
into pET-21a (Novagen) between NdeI and XhoI. The cDNA
for Tim was a gift of Dr. David Siderovski (University of North
Carolina).
Tim constructs were expressed in the Escherichia coli strain
Rosetta (DE3) (Novagen). Cell cultures were grown at 37 °C in
LB/ampicillin (100 g/ml), and induced with 1 mM isopropyl
-D-thiogalactopyranoside for 5 h at 27 °C. Cell pellets were
resuspended in 20 mM HEPES, pH 7, 1 mM EDTA, 2 mM dithi-
othreitol, 10% glycerol (buffer A) containing 20mMNaCl, lysed
using an Emulsiflex C5 cell homogenizer (Avestin), and clari-
fied by centrifugation at 40,000  g for 45 min at 4 °C. Clarified
supernatant was loaded on a Fast Flow S column (GE Health-
care) equilibrated with buffer A and eluted with a linear gradi-
ent of 20–500 mMNaCl. Tim protein eluted at 300 mMNaCl
and was loaded onto an S-200 size exclusion column (GE
Healthcare) equilibrated with buffer A containing 300 mM
NaCl. Fractions containing monomeric Tim were pooled, con-
centrated, and stored at 80 °C. Mutations were introduced
into wild-type Tim using the QuikChange site-directed
mutagenesis kit (Stratagene) as per the manufacturer’s instruc-
tions, and thesemutant proteins were expressed and purified as
described above. DNA sequences of all expression constructs
were verified by automated sequencing. RhoA was purified as
described (14–16).
Baculoviruses encoding both the wild-type and kinase inac-
tive (K297A) versions of the kinase domain of c-Src (Mus mus-
culus) were generated from pFastBacHT vectors (gifts of Dr.
David Siderovski, UNC) using the Bac-to-Bacmethod (Invitro-
gen). HighFive insect cells were infectedwith the baculovirus at
a multiplicity of infection of 1.0. After 48 h of incubation at
27 °C, cells were harvested by low speed centrifugation, resus-
pended, and lysed in 20mMHEPES, pH7.5, 500mMNaCl, 2mM
MgCl2, 10% glycerol (buffer B) with 10 mM imidazole, and clar-
ified by centrifugation at 100,000  g for 45 min. The clarified
supernatants were diluted to a final volume of 150 ml and
loaded onto a nickel-charged metal chelating column (GE
Healthcare) equilibrated with buffer B containing 10 mM imid-
azole, washed with buffer B containing 50 mM imidazole and
eluted with buffer B containing 400 mM imidazole. Eluted Src
was extensively dialyzed versus buffer B with 150 mMNaCl and
1 mM EGTA, concentrated, and stored at 80 °C.
The kinase domain of EphA4 was PCR amplified from the
full-length cDNA (gift of N. Mochizuki, National Cardiovascu-
lar Center Research Institute, Suita, Osaka, Japan), ligated into
pGEX4T2 (Amersham Biosciences) in frame with an N-termi-
nal GST tag, and expressed in BL21(DE3) E. coli as described
above. Cell pellets were resuspended in 20mMTris, pH 7.5, 150
mM NaCl, 1 mM EDTA, 2 mM dithiothreitol, 10% glycerol
(buffer C), lysed, and clarified as described above. Clarified
lysate was loaded onto a glutathione-Sepharose column (GE
Healthcare). EphA4 protein was washed and eluted in buffer C
containing 10 mM glutathione. The GST tag was removed with
TEV protease and protein was loaded on an S-200 column
equilibratedwith buffer C. Eluted EphA4was concentrated and
stored at 80 °C.
Guanine Nucleotide Exchange Assays—Fluorescence spec-
troscopic analysis of N-methylanthraniloyl (mant)-GTP incor-
poration into RhoA was carried out as described (17). In brief,
assay mixtures containing 20 mM Tris, pH 7.5, 150 mM NaCl, 5
mM MgCl2, 1 mM dithiothreitol, and 100 M mant-GTP
(Molecular Probes) and 2 M RhoAwere allowed to equilibrate
with continuous stirring. After equilibration, 50 nM Tim was
added and nucleotide loading wasmonitored as the decrease in
the tryptophan fluorescence (ex  295 nm, em  335 nm) of
RhoA or the increase in themant-GTP fluorescence (ex  360
nm, em  440 nm) as a function of time using a PerkinElmer
Life Sciences LS 55 spectrophotometer. Rates of guanine nucle-
otide exchange were determined by fitting the data to a single
exponential decaymodel withGraphPad Prizm.Datawere nor-
malized to yield percent GDP released and assays were per-
formed in duplicate.
Cell Culture and Transformation Assays—NIH 3T3 mouse
fibroblasts were maintained in Dulbecco’s modified Eagle’s
medium supplemented with penicillin/streptomycin and 10%
calf serum (Hyclone). HEK 293T cells and SYF fibroblasts were
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with penicillin/streptomycin and 10% fetal bovine
serum (Sigma). PCR-amplified Tim constructs were ligated
into pcDNA 3.1 Hygro (Invitrogen) between EcoRI and XhoI
such that an expressed HA-tag was encoded at the N terminus
of each construct. Mutations were introduced into wild-type
Tim as described above.
Cell lines stably expressing Tim were established by trans-
fectingNIH 3T3 cells with 1g of each pcDNA construct using
Lipofectamine Plus (Invitrogen) according to the manufactur-
er’s protocol. Three days post-transfection the cells were sub-
cultured into growthmedium supplemented with 300 g/ml of
hygromycin B. Mass populations of multiple, drug-resistant col-
onies (50) were pooled together for focus formation analyses.
Western blot analysis with an anti-HA antibody (Covance) was
performed to verify Tim expression in the cell lines.
For the secondary focus formation assays, equal numbers of
cells from each cell line were seeded into 60-mm dishes. The
growthmedium of each dish was replaced with fresh hygromy-
cin-supplemented medium every 3 days. 14 days after seeding,
the dishes were stained with crystal violet and the foci were
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quantified by visual inspection. Individual experiments were
performed in duplicate and independently carried out three
times.
GTPase Activation Assays—Affin-
ity purifications of RhoAwere carried
out as described (18). In brief, theRho
binding domain of Rhotekin (amino
acids 7–89) was expressed as a GST
fusion protein in BL21(DE3) cells and
immobilized on glutathione-coupled
Sepharose 4B beads (Amersham
Biosciences). HEK 293T cells were
transiently transfected with 1 g
of various pcDNA-Tim constructs
using Lipofectamine 2000 (Invitro-
gen) according to the manufactur-
er’s protocol. Immediately post-
transfection, these cells were serum
starved in Dulbecco’s modified
Eagle’s medium supplemented with
0.1% fetal bovine serum and incu-
bated for 16 h. Cells were washed in
ice-cold phosphate-buffered serum
and lysed in lysis buffer (50mMTris,
pH7.5, 500mMNaCl, 30mMMgCl2,
0.1% SDS, 0.5% sodium deoxy-
cholate, 1.0%Triton X-100 and pro-
tease inhibitors). Lysates were clari-
fied by centrifugation at 16,000  g
for 10min. Total protein concentra-
tion of the lysates was determined
by a colorimetric assay (Bio-Rad). 1
mg of clarified HEK 293T lysate was
incubated with 120 g of GST-Rho-
tekin-Rho binding domain beads for
1 h at 4 °C. The beads were washed
three times in wash buffer (25 mM
Tris, pH 7.5, 30 mM MgCl2, 40 mM
NaCl and protease inhibitors). Total
and affinity purified lysates were
subjected to SDS-PAGE and West-
ern blot analysis using an anti-RhoA
(Santa Cruz Biotechnology) mono-
clonal antibody. Each experiment
was performed a minimum of three
times. Precipitation of Tim with
recombinant G17A RhoA was per-
formed essentially as described (19).
In Vitro Kinase Assay—30 g of
purified Tim protein was incu-
bated with 250 ng of recombinant
Src or EphA4 kinase domain in
kinase buffer (100mMTris, pH 7.5,
125 mM MgCl2) supplemented
with 100 M ATP and 5 Ci of
[-32P]ATP for 60 min at 30 °C.
Samples were subjected to SDS-
PAGE and autoradiography. Con-
trol substrate peptide was obtained from Upstate.
Immunoprecipitation—The cDNAs for various Src con-
structs in pUSEamp were obtained from Upstate. SYF fibro-
FIGURE 1. Tim is specific for RhoA, RhoB, and RhoC. The exchange of GDP bound to various Rho GTPases and
catalyzed by Tim was measured using a standard fluorescence-based assay (14, 17). The relative fluorescence
units (RFU) resulting from mant-GTP loading onto each GTPase are shown for Tim catalyzed (red curves) and
intrinsic (black curves) exchange reactions. The GTPases were purified and assessed for GTP loading stimulated
by EDTA as previously described (51).
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blasts were transfected with 10 g of Src and 5 g of Tim using
Superfect (Qiagen) according to the manufacturer’s protocol.
24 h post-transfection, the cells were serum starved in Dulbec-
co’s modified Eagle’s medium supplemented with 0.1% fetal
bovine serum and incubated for 16 h. Cells were washed in
ice-cold phosphate-buffered serum and lysed in lysis buffer.
Lysates were clarified by centrifugation at 16,000  g for 10
min. 1 mg of clarified SYF lysate was incubated with 25 g of
anti-HA affinity matrix (Roche) for 1 h at 4 °C. The beads were
washed three times in lysis buffer. Total and affinity purified
lysates were subjected to SDS-PAGE andWestern blot analysis
using anti-phosphotyrosine (Transduction Laboratories), anti-
Src (Upstate), anti-HA (Covance), and anti--actin (Sigma)
antibodies. The experiment was performed three times.
RESULTS
Specificity of the Guanine Nucleotide Exchange Activity of
Tim—Previous studies by our laboratory have shown that Tim
catalyzes exchange of guanine nucleotides on RhoA, but not on
Rac1 or Cdc42 (16). This specificity of exchange activity is due
to the fact that Tim possesses a basic residue in helix 5 of the
DH domain, which is able to form an energetically favorable
salt-bridge interaction with glutamate 54 of RhoA. Rac1 and
Cdc42 does not have an acidic residue in the position analogous
toGlu-54 of RhoA, and thus cannotmake this contact withTim
(16).However, recentwork inwhich
Tim is overexpressed in various
mammalian cell types suggests that
Tim may catalyze exchange on
more than one Rho family GTPase.
For example, expression of Tim in
COS-7 or NIH 3T3 cells leads to a
loss of actin stress fibers and the for-
mation of membrane ruffles, dorsal
ruffles, and filopodia, suggesting
that Tim may activate Rac1, RhoG,
or Cdc42 but not RhoA in these cell
types (13). However, expression of
Tim in COS-7 cells leads to activa-
tion of RhoA, and not Rac1 or
Cdc42, in pulldown experiments
using GST-tagged versions of the
Rho-binding domains of the Rho
effector, Rhotekin, and the Rac1 and
Cdc42 effector, Pak (11). In the
same study, Tim expression in NIH
3T3 cells led to activation of JNK,
SRF, and AP-1-regulated transcrip-
tion, suggesting that Tim activates
multiple GTPases in this cell type.
However, in the same work, Tim
expression in Swiss 3T3 cells led to
cell rounding, whereas Tim expres-
sion in HeLa cells led to an increase
in vinculin-enriched focal adhe-
sions, suggesting that Tim activates
RhoA in these cell types.
In an attempt to resolve these
conflicting data, and to test the hypothesis that Tim activates
multiple GTPases, we performed a fluorescence-based guanine
nucleotide exchange assay on a library of Rho-family GTPases
(Fig. 1). In this assay, Tim robustly activated each of the mem-
bers of the RhoA subfamily of Rho GTPases, RhoA, RhoB, and
RhoC. However, Tim failed to activate members of the Rac1
(Rac1, Rac2, Rac3, and RhoG) or Cdc42 (Cdc42, TCL, and
TC10) subfamilies. These data suggest that Tim directly acti-
vates members of the RhoA subfamily of GTPases, but may
indirectly activate additional GTPases when overexpressed in
various cell types.
Regulation of Timby Regions Preceding Its DHDomain—Tim
was originally identified by its capacity to transform NIH 3T3
cells upon N-terminal truncation (10). Because many Dbl-fam-
ily proteins are activated by similar truncations, we undertook a
detailed analysis of the structural determinants within the
N-terminal region of Tim required for its auto-inhibition.
Using purified proteins, full-length Tim (wt, Fig. 2A) enhanced
the rate of exchange of guanine nucleotide bound to RhoA by a
modest 5-fold relative to the equivalent, spontaneous reaction
(). In contrast, truncation of the first 22 residues of Tim (22)
greatly enhanced the normalized loading of nucleotide bymore
than 30-fold.
Constitutive RhoA activation promotes cellular transforma-
tion, and consistent with the in vitro exchange data, stable
FIGURE 2. Full-length Tim is auto-inhibited by its N-terminal region. A, the exchange of GDP bound to RhoA
and catalyzed by Tim was measured using a standard fluorescence-based assay (14, 17). -Fold activation is
relative to the spontaneous loading of guanine nucleotide and represents the average of two independent
reactions for each trace. Equal amounts (2 g) of purified proteins used in the exchange assays are shown at the
right following SDS-PAGE and staining with Coomassie Brilliant Blue. Also shown is a schematic of the domain
architecture of Tim with the site of N-terminal truncation indicated. B, N-terminal truncated Tim potentiates
transformation of NIH 3T3 cells. Data represent the averages of three independent experiments carried out in
duplicate. ** denotes p  0.01, as determined by a pairwise t test assuming equal variances. Inset illustrates
representative plates of foci. Right panel verifies approximately equal expression of Tim variants used in the
focus formation assays. wt, wild type; IB, immunoblot.
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expression in NIH 3T3 cells of Tim (22) promoted robust
formation of foci relative to background (vector) and full-
length Tim (wt) (Fig. 2B). The combined results from the in
vitro exchange assays and cellular transformation assays indi-
cate that Tim is auto-inhibited by its N terminus and that dele-
tion of the first 22 residues of Tim relieves this auto-inhibition
to promote robust guanine nucleotide exchange on RhoA in
vitro as well as significant transformation of NIH 3T3 cells.
To produce a high-resolution map of the residues within the
N-terminal portion of Tim necessary for auto-inhibition, this
region was subjected to alanine-scanning mutagenesis and the
resulting purifiedmutant proteinswere tested for their capacity
to activate RhoA in vitro (Fig. 3A). This analysis identified res-
idues 15–22 of Tim as necessary for its auto-inhibition in vitro.
Stable expression of these substituted forms of Tim inNIH 3T3
cells indicated an approximate direct correlation between the
capacity of Tim to activate RhoA in vitro and the transforma-
tion potential of themutated formsofTim (Fig. 3B).One excep-
tion to this rule, Y22A, significantly relieved the auto-inhibition
of Tim in vitro, but failed to activate the transforming potential
of Tim. It was reasoned that in the cellular environment sec-
ondary intermolecular interactions might serve to stabilize the
auto-inhibited state. These secondary stabilizing interactions
would be lacking in the in vitro exchange assays using purified
components such that even modest perturbation to the auto-
inhibition of Tim (e.g.Y22A)would appear relatively enhanced.
FIGURE 3. A short region within Tim is responsible for auto-inhibition.
A, the N-terminal portion of Tim was subjected to scanning mutagenesis and
the purified proteins were assayed for their capacity to catalyze the exchange
of guanine nucleotides on RhoA. -Fold activation is relative to the spontane-
ous loading of nucleotide onto RhoA () and represents the average of two
independent assays for each mutant. Equal amounts (2 g) of purified pro-
teins used in the exchange assays are shown in the lower panel following
SDS-PAGE and staining with Coomassie Brilliant Blue (a composite of several
gels is shown). B, equivalent forms of Tim were stably expressed in NIH 3T3
cells (lower panel, composite Western blot) and assayed for foci formation
(upper panel). Data represent the averages of three independent experiments
carried out in duplicate. *, denotes p  0.05; **, denotes p  0.01, as deter-
mined by a pairwise t test assuming equal variances. wt, wild type.
FIGURE 4. The N-terminal region is necessary and sufficient for Tim auto-
inhibition. A, Tim (22) was incubated with either a peptide corresponding
to the N-terminal auto-inhibitory region (WT, biotin-SQLLYQEYSDV-amide) or
a mutant peptide (MT, biotin-SQLLEQEYSDV-amide) at room temperature for
20 min. The resulting complexes were assayed for their ability to stimulate
loading of mant-GTP onto RhoA. The peptide concentrations were 100 M.
B, the activity of Tim constructs transiently expressed in quiescent HEK 293T
cells was assessed by a pulldown assay using GST-tagged nucleotide-free
RhoA as the affinity purification matrix. Levels of active Tim were determined
by immunoblotting the pulldown samples. Immunoblots (IB) of the total cell
lysate (2.5% input shown) show approximately equal expression of the Tim
constructs. C, the ability of Tim constructs to stimulate GTP loading on RhoA
in HEK 293T cells was assessed by affinity precipitation of active RhoA with
rhotekin. Levels of RhoA-GTP were determined by immunoblotting the affin-
ity precipitated samples and were compared with RhoA pools in the total cell
lysate (1% input shown). In the same experiment, HA-tagged Tim variants
were checked for approximately equal expression by immunoblotting.
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To explore this possibility, Tyr-22was subsequentlymutated to
Glu (Y22E)with the anticipation that the added negative charge
would further perturb auto-inhibitory interactions. The identi-
cal substitution was separately created at Tyr-19, and the
resulting mutant proteins were analyzed as above. Both poten-
tially phosphomimetic substitutions led to robust in vitro acti-
vation of RhoA and correspondingly large increases in the
transformation potential of Tim. To the best of our knowledge,
these data represent the first report of a full-length Dbl-family
protein that is activated by single substitutions to the same
extent as activation by N-terminal truncation.
To determine whether residues 15–22 of Tim are sufficient
for its auto-inhibition, we created a peptide comprising this
region and performed an in vitro guanine nucleotide exchange
assay in which this peptide (WT, Fig. 4A) was added to Tim
(22) in trans. The exchange activity of Tim (22) alone was
greatly enhanced with respect to full-length Tim, as was also
shown in Fig. 1A. However, the exchange activity of Tim (22)
in the presence of the wild-type peptide was reduced to that of
full-length, auto-inhibited Tim. To determine whether the
observed inhibition was specific for this peptide, we also cre-
ated a peptide in which the tyrosine residue corresponding to
Tyr-19 in full-length Tim was converted to glutamic acid (MT,
Fig. 4A). Substitution of Tyr-19 with glutamic acid in the con-
text of full-length Tim led to Tim activation in both the in vitro
exchange assay and the cellular transformation assay (Fig. 3).
We therefore expected that a peptide incorporating this substi-
tution would have no effect on the exchange potential of Tim
(22). This hypothesis was borne out experimentally, because
the exchange potential of Tim (22)
in the presence of the mutant pep-
tide was identical to that of Tim
(22) alone. Importantly, neither
peptide had an effect on the intrin-
sic rate of exchange on RhoA. These
data strongly suggest that residues
15–22 are both necessary and suffi-
cient for Tim auto-inhibition.
To confirm that the N-terminal
region is necessary for Tim inhibi-
tion in the context of an intact cell,
we performed affinity purifications
of active Tim using a GST-tagged
version of nucleotide-free RhoA
(RhoA G17A, Fig. 4B). Because
Dbl-family proteins bind preferen-
tially to nucleotide-free Rho family
GTPases, this construct is expected to
affinity purify any active, RhoA-spe-
cific GEF present in a cell lysate.
Wild-type, HA-tagged Tim, when
expressed in serum-starved HEK
293T cells, did not appreciably
interact with RhoA G17A. In con-
trast, both truncated Tim (22) and
full-length Tim possessing the dou-
ble substitution, Y19EY22E, were
robustly affinity purified by the
RhoA G17Amatrix, suggesting that the immediate N-terminal
region of Tim, and tyrosines 19 and 22 in particular, lead toTim
auto-inhibition by preventing its interaction with RhoA.
Affinity purifications of active RhoA (Fig. 4C) confirmed the
direct correlation between the capacity of Tim to activate RhoA
in vitro and the transforming potential of Tim. For example,
whereas wild-type Tim did not significantly activate RhoA rel-
ative to empty vector upon transfection intoHEK293Tcells, both
truncated Tim (22) and full-length Tim possessing the double
substitution, Y19EY22E, dramatically stimulated the loading
of GTP onto RhoA. These data strongly suggest that the
increased transformation potential of mutant forms of Tim are
directly caused by their increased in vivo exchange activities.
Regulation of Tim by Tyrosine Phosphorylation—Based upon
primary and secondary amino acid sequence analyses, the auto-
inhibitory region within Tim is strongly predicted to be helical
(residues 16–26; (20)) and tyrosines 19 and 22 within this
region are predicted to be excellent substrates for phosphoryl-
ation by Src-family non-receptor tyrosine kinases (21). Because
the activation ofmanyDbl-familyGEFs is associatedwith phos-
phorylation (22), the potential regulation of Tim by phospho-
rylation was tested both in vitro and in vivo (Fig. 4). First, it was
confirmed that indeed, full-length, purified Tim was an excel-
lent substrate for purified Src, with kinetics and extent of phos-
phorylation resembling control reactions with a standard, con-
trol peptide (Fig. 5A and data not shown). Furthermore,
phosphorylationwas confined to theN-terminal region of Tim,
because Src was incapable of phosphorylating Tim (22). Res-
idues 19 and 22 are the only tyrosines encompassed within this
FIGURE 5. Src phosphorylates Tim and activates its exchange activity. A, Src specifically phosphorylates
two tyrosines (19 and 22) within the auto-inhibitory helix of Tim. Purified forms of Tim (lower panel) were
incubated with recombinant Src and radioactive ATP for various times prior to SDS-PAGE and auto-radiogra-
phy was used to assess levels of phosphorylation (upper panel). Deletion of the entire inhibitory region (22), or
tandem substitution of Tyr-19 and Tyr-22 abrogates phosphorylation. B, Src phosphorylates Tim in vivo. SYF
fibroblasts were transiently cotransfected with HA-Tim and constitutively active (CA) or kinase dead (KD) Src
constructs. HA-Tim was immunoprecipitated from cell lysates, and immunoblotted (IB) to determine the extent
of phosphorylated Tim. The experiment was performed three times and a representative example is shown.
Phosphorylation of Tim by Src (C) or EphA4 (D) promotes the capacity of Tim to catalyze nucleotide exchange
on RhoA. Full-length Tim was incubated with combinations of kinase and ATP as indicated for 30 min prior to
addition of the mixtures to exchange reactions. -Fold activation is relative to the spontaneous loading of
nucleotide onto RhoA (black trace) and represents the average of two independent runs for each condition. wt,
wild type.
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deletion, and both residues are phosphorylated by Src because
substitution at both sites (Y19AY22A) is required to prevent
the phosphorylation of full-length Tim. Intriguingly, single
substitution at either Tyr-19 or Tyr-22 enhances phosphoryla-
tion at the other tyrosine, indicating that the two sites might be
functionally linked. One simple interpretation for these data
posits that substitution at either tyrosine significantly disrupts
intramolecular interactions associated with auto-inhibition
such that the remaining tyrosine is more accessible for phos-
phorylation by Src.
A logical extension of this scenario is that phosphorylation at
tyrosines 19 and 22might be physiologically relevant for reliev-
ing the auto-inhibition of Tim in vivo. Consequently, it was
shown that constitutively active but not kinase dead (KD) Src
was capable of phosphorylatingTim in vivoupon co-expression
in SYF fibroblasts designed to lack endogenous Src-family
kinases (Fig. 5B). In the same vein, Src robustly activatedTim in
vitro using purified components (Fig. 5C). In this setting, max-
imal activation required ATP consistent with the idea that
phosphorylation of Tim by Src relieves auto-inhibition of Tim
to promote activation of RhoA. Taken together, these data
strongly suggest that the in vivo phosphorylation of Timwithin
its auto-inhibitory region by Src might be a physiologically rel-
evant means of activating the exchange potential of Tim and
linking as yet unidentified upstream cellular events with the
activation of RhoA.
Srcwithout ATP also activatedTim (Fig. 5C), suggesting that
the binding of Src toTimpartially disrupted the auto-inhibition
of Tim.However, the possibility exists that Src remained bound
to ATP during purification of the kinase domain, and that addi-
tional ATP is not required for this kinase domain to phospho-
rylate Tim. To test this hypothesis, we incubated Tim with
increasing amounts of the purified Src kinase domain and per-
formed a phosphotyrosine blot (Fig. 6A). Auto-phosphoryla-
tion of the kinase domain, and phosphorylation of Tim, only
occurred when ATP was included in the reaction, suggesting
that the purified Src kinase domain is not bound to ATP. To
confirm that Src binding to Tim, in the absence of phosphoryl-
ation, activates Tim, we also performed an exchange assay in
which Tim was incubated with a kinase inactive (K297A) ver-
sion of Src (Fig. 6B). Kinase inactive Src was also able to activate
Tim, indicating that formation of a complex between Src and
Tim, decoupled from phosphorylation, is sufficient to partially
activate the exchange capacity of Tim.We have been unable to
isolate a complex of Tim and Src by co-immunoprecipitation
experiments from cells over-expressing both of the proteins
(data not shown), suggesting that their interaction is transient
in vivo where endogenous concentrations of ATP favor com-
pletion of the phosphorylation reaction.
The Tim homologs, ephexin and Vsm-RhoGEF, interact with
and are tyrosinephosphorylateddownstreamof theEphA4 recep-
tor tyrosine kinase (23, 24). To test the hypothesis that Tim is
directly phosphorylated by EphA4, we performed in vitro kinase
assays with the recombinant kinase domain of EphA4. Tim was
robustly phosphorylated by the kinase domain of EphA4 (data not
shown), indicating that Tim is phosphorylated by EphA4 directly.
Additionally, EphA4 activated Tim in vitro (Fig. 5D). In this case,
the kinase in the absence of ATP did not activate Tim, suggesting
that the interaction between EphA4 and Tim is transient com-
pared with the interaction between Tim and Src. These data sug-
gest that binding of ligand to the EphA4 receptor may lead to the
phosphorylation and activation of Tim.
Disrupting Auto-inhibition by Mutating the DH Domain—
The above experiments have shown that Tim is auto-inhibited
by a small, conserved region with high helical propensity and
that this auto-inhibition can be relieved by truncation, muta-
tion, or phosphorylation of the auto-inhibitory region. This sit-
uation is reminiscent of regulation of theVav isozymeswhereby
a short helix immediately preceding the DH domain lies down
FIGURE 6. The Src kinase domain activates Tim in the absence of phos-
phorylation. A, ATP is required for the phosphorylation of Tim by recombi-
nant Src produced in baculovirus-infected HighFive cells. Various combina-
tions of Tim and Src were incubated for 30 min at 37 °C prior to SDS-PAGE and
immunoblot (IB) analysis. B, kinase-inactive Src activates Tim. Full-length Tim
was incubated with combinations of kinase-inactive Src as indicated for 30
min prior to addition of the mixtures to exchange reactions. -Fold activation is
relative to the spontaneous loading of nucleotide onto RhoA (black trace) and
represents the average of two independent runs for each condition. Equal
amounts of the purified Src proteins are shown in the lower panel following
immunoblot analysis.
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on the most conserved surface of the DH domain to prevent
Rho GTPases from engaging this same surface for effective
nucleotide exchange (25). Phosphorylation of the inhibitory
helix in the Vav isozymes by Src and related non-receptor tyro-
sine kinases stimulates exchange in vitro and in vivo (26–30)
and is required for some physiological functions of Vav (31). If a
similar mechanism is operative for Tim, then it might be pos-
sible to mutate specific residues within the DH domain to dis-
rupt interactions with the auto-inhibitory helix without affect-
ingGTPase binding, and in thisway constitutively activateTim.
Such residues within the DH domain would be expected to be
conserved, equivalent to sites that contact the auto-inhibitory
helix of Vav1, and yet not critical for the interaction of the DH
domain with GTPases. Appropriate analyses of the available
sequence and structure data (Fig. 7A) identified several sites
that fit these criteria, and Tim was mutated with individual
substitutions (Y111L and S114A) to test this hypothesis. Tim
(Y111L) was destabilized, insoluble and inactive in vitro (data
not shown). In contrast, Tim (S114A) is stable, soluble, and able
to activate RhoA in vitro (Fig. 7B)4-foldmore efficiently than
wild-type Tim. Importantly, under identical conditions, S114A
is relatively silent within the context of Tim lacking the auto-
inhibitory helix (22), indicating that the intrinsic exchange
mechanism of Tim is unaffected by S114A. The ability of this
mutant (22 S114A) to catalyze exchange, however, is inhib-
ited by addition of 100 M of the peptide corresponding to the
N-terminal putative helical motif (residues 15–25) of Tim used
in Fig. 4A (data not shown). This result indicates that the S114A
substitution does not completely abolish the interaction
between the N-terminal auto-inhibitory motif of Tim and the
DH domain pocket and is consistent with the partial relief of
inhibition of exchange caused by the S114A substitution within
the context of full-length Tim (Fig. 7A).
Consistent with the in vitro exchange data, Tim (S114A)
behaved similarly to truncated Tim (22) in its ability to inter-
act with nucleotide-free RhoA (Fig. 7C) and its ability to induce
formation of foci (Fig. 7D). Consequently, it is possible to
decouple the auto-inhibitory and exchange functions of Tim
through mutation of its DH domain.
DISCUSSION
Fig. 8 presents a model for the relief of auto-inhibition of
Tim. In this model, an auto-inhibitory helix packs against the
conserved pocket of the DH domain in the basal, inactive state
to prevent Rho GTPases from accessing the surface of the DH
domain necessary for guanine nucleotide exchange. Activation
of Src leads to phosphorylation of the auto-inhibitory helix,
which disrupts the interactions between the auto-inhibitory
helix and the DH domain, thereby freeing the DH domain to
interact with cognate GTPases and activate them by nucleotide
exchange. If the auto-inhibitory helix is truncated, or otherwise
mutated such that it can no longer bind to theDHdomain, Tim
will be constitutively activated. Likewise, if residues within the
conserved binding patch of the DH domain are mutated such
FIGURE 7. Mutations within the DH domain designed to disrupt the interaction with the auto-inhibitory helix lead to auto-activation. A, surface
representations of the Vav1 DH domain (Protein Data Bank accession 1F5X, murine Vav1 residues 198 –372) that illustrate: left, the positions of highly conserved
residues among DH domains from 70 human Dbl-family sequences as determined by ClustalX (bright red is most conserved); center, the sites of contact (5 Å;
blue) between the Vav1 DH domain and the Vav1 auto-inhibitory helix (residues 170 –179); and right, the sites and degree of conservation of interactions
observed within the structures of Tiam1Rac1, IntersectinCdc42, DbsRhoA, and LargRhoA that occur between Rho GTPases and DH domains (3.5 Å between
residues, bright green is fully conserved) mapped onto the surface of the DH domain of Vav1. Surface representations were produced using the programs
ProtSkin (49) and PyMOL (50) and reveal a region of high sequence conservation in a pocket that contacts the auto-inhibitory helix but does not contact Rho
GTPases. Thr-212 of Vav1 is indicated and the equivalent residue (Ser-114) in Tim has been mutated to disrupt auto-inhibition as shown below. B, relative to the
spontaneous loading of guanine nucleotide onto RhoA (, black trace) auto-inhibition of full-length Tim (wt, red trace) is relieved by mutation within its DH
domain (S114A, green trace), whereas the exchange activity of truncated, constitutively active Tim (22, magenta trace) is relatively unaffected by the equiv-
alent mutation (22  S114A, blue trace). The traces corresponding to spontaneous loading, full-length Tim, and Tim (22) are reproduced from Fig. 2 for
reference. Proteins used in the exchange assays are shown at right. C, the S114A mutation increases the ability of Tim transiently expressed in quiescent HEK
293T cells to associate with nucleotide-free RhoA. The activity level of Tim constructs was assessed as described in the legend to Fig. 4. Levels of active Tim were
determined by immunoblotting the pulldown samples. Immunoblots (IB) of the total cell lysate (2.5% input shown) show approximately equal expression of
the Tim constructs. D, mutation in the DH domain (S114A) increases the ability of Tim to induce foci when expressed in NIH 3T3 cells. Data represent the
averages of three independent experiments carried out in duplicate. The lower panel shows approximately equal expression of the Tim constructs.
FIGURE 8. Model of Tim auto-inhibition. A, regulation of Tim exchange
activity by sequences N-terminal to the DH domain. The auto-inhibitory helix
packs against the conserved pocket of the DH domain, preventing the bind-
ing and consequent activation of the cognate Rho GTPase. Tyrosine phos-
phorylation leads to the removal of the auto-inhibitory helix from the DH
domain. Tim can now bind Rho to catalyze the exchange of guanine nucleo-
tide. B, mechanisms of constitutive activation of Tim proteins. The auto-inhib-
itory helix is truncated, or otherwise mutated such that it can no longer bind
to the DH domain. Alternatively, residues within the conserved binding patch
of the DH domain are mutated such that it is no longer able to bind the
auto-inhibitory helix, leading to a constitutively active GEF. In each of these
scenarios, the end result is loss of auto-inhibition leading to constitutive acti-
vation of Tim.
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that it is no longer able to bind the auto-inhibitory helix, Tim
will be constitutively activated.
Timclusterswith five other humanDbl-family proteins: neu-
roblastoma, Sgef,Wgef, Ngef, andVsm-RhoGEF, based on high
sequence identity among DH domains and overall domain
architecture that includes an SH3 domain C-terminal to the
canonical DH/PH module. Whereas not readily evident using
standard sequence alignment algorithms such as PSI-BLAST,
all members of this subgroup possess a putative auto-inhibitory
region N-terminal to the DH domain with high sequence iden-
tity to the short auto-inhibitory regionmapped inTim (data not
shown). Consequently, it is likely that other members of this
subgroup are regulated in a manner similar to Tim. In fact, the
mouse homolog of Ngef, ephexin, is tyrosine phosphorylated in
an N-terminal motif with significant sequence identity to the
auto-inhibitory helix within the Tim subgroup of Dbl proteins.
However, phosphorylation of ephexin alters its exchange pro-
file. Specifically, unphosphorylated ephexin activates RhoA,
Rac1, and Cdc42; but when tyrosine phosphorylated, ephexin
exclusively activates RhoA (32). The mechanism by which this
specificity switch occurs is currently unknown and not encom-
passed within themodel presented here for the activation of Tim.
Themechanism of auto-inhibition of Tim presented above is
reminiscent of the mechanism of auto-inhibition of the Vav
isozymes. In fact, the auto-inhibitory helix of Tim shows high
sequence homology to the auto-inhibitory helix of Vav1 (data
not shown). The structure of an extended fragment of the DH
domain of Vav1 highlights the steric occlusion of the DH
domain through interaction with an N-terminal helix to pre-
vent GTPase binding and guanine nucleotide exchange (25).
This inhibition is relieved upon phosphorylation of Tyr-174
within the inhibitory helix, which disrupts the interaction of the
inhibitory helix with the DH domain and allows Rho GTPases
to access the catalytic surface of the DH domain for effective
guanine nucleotide exchange. Whereas this regulatory mecha-
nism is operative in vivo for the three Vav isozymes, complete
regulation ofVav isozymes ismore complex. For example, Vav1
is additionally phosphorylated at Tyr-142 and Tyr-160 within a
highly acidic region, and substitution of all three tyrosines to
phenylalanine greatly enhances the transformation potential of
full-length Vav1 relative to any single substitution. However, a
mutant of Vav1 truncated to remove its N-terminal calponin
homology domain, but not the phosphorylated tyrosines, is also
transforming, suggesting that the calponin homology domain
stabilizes interactions of the auto-inhibitory helix with the DH
domain within the context of full-length Vav1 (7). In addition,
the calponin homology domain contributes to the auto-inhibi-
tion of Vav proteins by interacting with a cysteine-rich domain
C-terminal to the DH/PH cassette (33, 34). Furthermore, Vav
proteins may also be regulated allosterically through the bind-
ing of phospholipids to the PH domain, although this concept
remains controversial (35, 36). Thus, the regulated activation of
the Vav isozymes is more complex than what we have shown
above for Timbecause the activation of Vav isozymes cannot be
attributed solely to the phosphorylation of tyrosine residues
N-terminal to the DH domain.
The human genome encodes 58 receptor tyrosine kinases,
and more than half of the receptor tyrosine kinases are known
to activate at least one of the Rho familymembers. At least 16 of
the 69 human Dbl-family proteins are known to interact with
and/or be phosphorylated by receptor tyrosine kinases, thus
serving as a link between ligation of receptor tyrosine kinases
and Rho activation (22). For instance, FRG, a Dbl-family pro-
tein specific for Cdc42, is activated upon phosphorylation by
Src downstream of signals arising from both the endothelin A
receptor (37) and nectins (38). Similarly, the exchange activity
of Dbs for Cdc42 is enhanced upon the phosphorylation of Dbs
by Src downstream of the 1B adrenergic receptor (39). Acti-
vated TrkB directly binds to and activates Tiam1 (40), which is
also known to be phosphorylated and activated by Src (41). In
each case mentioned above, the mechanisms by which phos-
phorylation increases exchange activity have yet to be deter-
mined. Clearly, one fruitful avenue of research will be to assess
mechanistically how these phosphorylations enhance exchange;
one likely mechanism is that phosphorylation perturbs auto-inhi-
bition as described here.
The Rho GTPases have long been thought to play a role in
tumorigenesis. However, in contrast to Ras GTPases, animal
studies and studies of human tumors have yet to further our
understanding of the role of RhoGTPases in promoting tumor-
igenesis. In fact, constitutively active, GTPase-deficient
mutants of RhoGTPases have yet to be found in human tumors.
However, several Rho GTPases, including RhoA, RhoC, and
Rac1, are over-expressed in human tumors, leading to the
hypothesis that Rho GTPases, unlike Ras GTPases, must
undergo cycling of GTP loading to be oncogenic (3, 42). Con-
sistent with this idea, Dbl-family Rho GEFs are more potent
oncogenes than their substrate GTPases. Although many Dbl-
family proteins, including Tim, were identified as proto-onco-
genes in expression library screens using DNA or RNA derived
fromhuman cancer cells, these activation events have proven to
be experimental artifacts.Of the 69 humanDbl-family proteins,
onlyTiam1has been shown to bemutated in human tumors (4),
althoughVav1 is ectopically expressed in someprimary pancre-
atic adenocarcinomas (43) and neuroblastomas (44). Themuta-
tions characterized in this study, both in the auto-inhibitory helix
and DH domain, represent potential mechanisms by which Tim
and other Dbl-family proteins might be activated in human
tumors. Identification of suchmutations in human tumors would
further define the role of Rho GTPases in tumorigenesis.
If versions of Timmutated in either the auto-inhibitory helix
or in the region of the DH domain thought to interact with the
auto-inhibitory helix should be isolated from human tumors,
then Tim would represent an attractive target for rational drug
design. The peptide inhibitor shown in Fig. 3A could serve as
the basis for design of peptidomimetic inhibitors of aberrant
Tim activation of Rho. Several inhibitors of small GTPase acti-
vation have been previously identified. TRIP was isolated as a
random peptide aptamer that selectively binds to the second
DHPH cassette of the RhoGEF Trio and inhibits the exchange
activity of Trio in vitro and in PC12 cells through an unknown
mechanism (45). Additionally, the small molecule NCS23766
was identified in structure-based virtual screen for compounds
that might fit into a pocket on the surface of Rac1. Residues in
this pocket contact Tiam1 during the exchange reaction. This
compound selectively inhibits Rac1 binding to Rac1-specific
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GEFs in vitro and prevents platelet-derived growth factor-in-
duced Rac activation in cells (46, 47). Finally, brefeldin A inhib-
its the activation of the small GTPase Arf1 by its exchange fac-
tors by binding to and stabilizing a complex of Arf1-GDP and
the catalytic Sec7 domain (48). The Tim peptide, then, is a
unique GEF inhibitor in that its mechanism of action is identi-
cal to that of the auto-inhibitory helix of the wild-type protein.
In summary, we have shown that the Dbl-family protein,
Tim, is a RhoA-, RhoB-, and RhoC-specific GEF that is auto-
inhibited by a putative helix N-terminal to the DH domain,
which directly binds the DH domain to sterically exclude Rho
GTPases and prevent their activation. This auto-inhibition is
relieved by truncation, mutation, or phosphorylation of the
auto-inhibitory helix, or by mutation of the conserved surface
of the DH domain to disrupt interactions with the auto-inhib-
itory helix. Because inhibition of Tim can be restored by addi-
tion of the auto-inhibitory helix in trans, the auto-inhibitory
helix is necessary and sufficient formaintenance of a basal state
of Tim activation.
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